Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 16Gynecologic 3Tumor-Agnostic 2Genitourinary 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × ribociclib × Genitourinary × Clear all
NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Thomas Jefferson University

Phase 1/2 Terminated
52 enrolled 31 charts
Genitourinary

Prostatic Neoplasms

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

University of California, San Francisco

Phase 1/2 Completed
43 enrolled 22 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡